Compact imaging technology, AI-driven diagnostics, and neurovascular robotics defined this week’s MedTech funding activity. Investors continued to back innovation, with capital spanning advanced X-ray platforms, endovascular robotics, neonatal monitoring, and women’s health devices. Here’s who raised capital.
Lumitron closes USD $50 million investment for HyperVIEW platform
Hancock Prospecting (led by Gina Rinehart) has invested $50M in Lumitron Technologies, with the option to increase its funding to USD $100 million this year. The capital is dedicated to commercial scale-up of Lumitron’s HyperVIEW platform, an advanced medical imaging and radiotherapy technology originally developed at Lawrence Livermore National Laboratory. The US FDA has already granted Breakthrough Device Designation to Lumitron’s breast cancer imaging technology.
Executive Chairman and co-founder Maurie Stang: “Hancock’s funding will enable Lumitron to produce the first commercially focused VHEE FLASH machine.”
Last week’s tracker: Tissium, CroíValve, and more
Nanoflex Robotics awarded €12.5 million from the EIC Accelerator
Nanoflex Robotics AG has secured €12.5 million in blended financing from the European Innovation Council Accelerator, consisting of a €2.5 million grant and a €10 million equity investment. The company was one of only 38 businesses selected across Europe from a pool of approximately 1,000 applicants, one of just four Swiss companies chosen, and the sole medical technology firm among them. Funds go toward completing clinical validation, securing CE marking, and bringing its telerobotics stroke-treatment platform to market.
CEO Matt Curran: “We are honored to have the EIC’s support, a powerful affirmation of our mission to close the gap in access to treatment between rural and urban communities.”
Cork’s NeuroBell secures $5.5M (€4.8M) in new funding for US launch
Funding supports US launch of LUNA, its AI-powered neonatal seizure-detection EEG monitor, alongside FDA clearance efforts. The funding round was led by Elkstone and saw participation from major existing investors alongside Parkview Health, a prominent US health system operating 15 hospitals.
Co-Founder and CEO Dr Mark O’Sullivan: “LUNA exists to put clinical-grade brain monitoring in the hands of every NICU team, wherever they are. This investment gives us the resources to scale that vision to patients in the US and across Europe.”
Materna closes $5 million B3 financing to fuel growth
The round was led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with continued support from existing investors. Funding will enable Materna to complete its EASE pivotal trial readout, expand Milli® channel access, and build out commercial manufacturing capabilities ahead of the anticipated Ellora™ Obstetrical System launch.
President and CEO Tracy MacNeal: “We are thrilled to be entering this next phase as we prepare for the Ellora launch, bringing an important innovation to women’s health.”
